title: Effect of acupuncture on naloxone-precipitated withdrawal syndrome in morphine-experienced rats: the mediation of GABA receptors.
abstract: Repeated morphine administration increases extracellular dopamine levels in the nucleus accumbens, which results in behavioral sensitization that can be suppressed by acupuncture at Shenmen (HT7) points. The present study was conducted to investigate the effects of acupuncture at HT7 on morphine withdrawal syndrome as well as to explore the role of GABA receptors in mediating the effects of HT7 acupuncture. We induced morphine withdrawal by injecting naloxone to rats that self-administer morphine and evaluated the effects of acupuncture and/or GABA receptor antagonists on their withdrawal symptoms. Acupuncture at HT7, but not at the control point LI5, significantly decreased symptoms of morphine withdrawal. HT7 inhibition of the withdrawal syndrome was blocked by pretreatment with either the GABA(A) receptor antagonist bicuculline or the GABA(B) antagonist SCH 50911. These findings suggest that the effects of acupuncture on suppression of morphine withdrawal syndrome are mediated, at least in part, through GABA receptors.
authors: College of Oriental Medicine, Daegu Hanny University, Daegu 706-828, South Korea.
authors: Ji Hye
authors: JH
authors: Lee
authors: Hee Young
authors: HY
authors: Kim
authors: Eun Young
authors: EY
authors: Jang
authors: Seong Hun
authors: SH
authors: Choi
authors: Chang Hyun
authors: CH
authors: Han
authors: Bong Hyo
authors: BH
authors: Lee
authors: Chae Ha
authors: CH
authors: Yang
mesh_terms: D015669:Acupuncture Points; D015670:Acupuncture Therapy; D000818:Animals; D001640:Bicuculline / Q000494:pharmacology; D003967:Diarrhea / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D058787:GABA-A Receptor Antagonists / Q000494:pharmacology; D058788:GABA-B Receptor Antagonists / Q000494:pharmacology; D008297:Male; D009020:Morphine / Q000009:adverse effects*; D009021:Morphine Dependence / Q000188:drug therapy; D009025:Morpholines / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009270:Naloxone / Q000009:adverse effects / Q000627:therapeutic use; D009292:Narcotic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology*; D018080:Receptors, GABA-B / Q000187:drug effects / Q000502:physiology*; D013375:Substance Withdrawal Syndrome / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D014202:Tremor / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology
chemical_list: C095804:(+)-(S)-5,5-dimethylmorpholinyl-2-acetic acid; D058787:GABA-A Receptor Antagonists; D058788:GABA-B Receptor Antagonists; D009025:Morpholines; D009292:Narcotic Antagonists; D011963:Receptors, GABA-A; D018080:Receptors, GABA-B; D009270:Naloxone; D009020:Morphine; D001640:Bicuculline